Suppr超能文献

寻找用于微创瓣膜手术的最佳心脏停搏液。

In search of optimal cardioplegia for minimally invasive valve surgery.

作者信息

Russell Sion, Butt Salman, Vohra Hunaid A

机构信息

Department of Cardiac Surgery/Cardiovascular Sciences, Bristol Heart Institute, University of Bristol, Bristol, UK.

Department of Perfusion Sciences, St George's Hospital, London, UK.

出版信息

Perfusion. 2022 Oct;37(7):668-674. doi: 10.1177/02676591211012554. Epub 2021 Jun 3.

Abstract

Cardioplegic solutions are used in cardiac surgery to achieve controlled cardiac arrest during operations, making surgery safer. Cardioplegia can either be blood or crystalloid based, with perceived pros and cons of each type. Whilst it is known that cardioplegia causes cardiac arrest, there is debate over which cardioplegic solution provides the highest degree of myocardial protection during arrest. Myocardial damage is measured post-operatively by biomarkers such as serum TnT, TnI or CK-MB. It is known that the outcomes of minimally invasive valve surgery are comparable to full sternotomy valve operations. Despite there being a wide diversity in use of different cardioplegic solutions across the world, this comprehensive literature review found no superiority of one cardioplegic solution over the other for myocardial protection during minimally invasive valve procedures.

摘要

心脏停搏液用于心脏手术中,以在手术期间实现可控的心脏骤停,从而使手术更安全。心脏停搏液可以是基于血液的,也可以是基于晶体的,每种类型都有其各自的优缺点。虽然已知心脏停搏液会导致心脏骤停,但对于哪种心脏停搏液在心脏停搏期间能提供最高程度的心肌保护存在争议。术后通过生物标志物如血清肌钙蛋白T(TnT)、肌钙蛋白I(TnI)或肌酸激酶同工酶(CK-MB)来测量心肌损伤。已知微创瓣膜手术的结果与全胸骨切开瓣膜手术相当。尽管世界各地使用的不同心脏停搏液种类繁多,但这项全面的文献综述发现,在微创瓣膜手术中,一种心脏停搏液在心肌保护方面并不优于另一种。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4dda/9500165/081b9e17d44b/10.1177_02676591211012554-fig1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验